Abstract
The extended classic ternary complex model predicts that a G protein-coupled receptor (GPCR) exists in only two interconvertible states: an inactive R, and an active R*. However, different structural active R* complexes may exist in addition to a silent inactive R ground state (Rg). Here we demonstrate, in a cellular context, that several R* states of 5-hydroxytryptamine-4 (5-HT4) receptors involve different side-chain conformational toggle switches. Using site-directed mutagenesis and molecular modeling approaches, we show that the basal constitutive receptor (R*basal) results from stabilization of an obligatory double toggle switch (Thr3.36 from inactive g- to active g+ and Trp6.48 from inactive g+ to active t). Mutation of either threonine or tryptophan to alanine resulted in a lowering of the activity of the R*basal similar to the Rg. The T3.36A mutation shows that the Thr3.36 toggle switch plays a minor role in the stabilization of R* induced by 5-HT (R*-5-HT) and BIMU8 (R*-BIMU8) and is fully required in the stabilization of R* induced by (S)-zacopride, cisapride, and 1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-butyl-4-piperidinyl)-1-propanone (RS 67333) (R*-benzamides). Thus, benzamides stabilize R*-benzamides by forming a specific hydrogen bond with Thr3.36 in the active g+ conformation. Conversely, R*-BIMU8 was probably the result of a direct conformational transition of Trp6.48 from inactive g+ to active t by hydrogen bonding of this residue to a carboxyl group of BIMU8. We were surprised that the Trp6.48 toggle switch was not necessary for receptor activation by the natural agonist 5-HT. R*-5-HT is probably attained through other routes of activation. Thus, different conformational arrangements occur during stabilization of R*basal, R*-5-HT, R*-benzamides, and R*-BIMU8.
Footnotes
-
This work was supported by the Centre National de la Recherche Scientifique; Institut National de la Santé et de la Recherche Médicale; Ministère Français de la Recherche [Grant ANR Blanc-2006-0087-02]; Universitéde Montpellier; Ministerio de Educación y Ciencia [Grants SAF2006-04966, SAF-2007-67008]; and Instituto de Salud Carlos III [RD07/0067/0008]. Binding experiments, cAMP measurement, and ELISA were carried out using facilities of the Pharmacological Screening platform of the Institut de Génomique Fonctionnelle.
-
L.P.P. and J.S. equally contributed to this work.
-
ABBREVIATIONS: GPCRs, G protein-coupled receptors; 5-HT, 5-hydroxytryptamine; 5-HT4R, 5-hydroxytryptamine-4 receptor; Rg, inactive R ground state; TM, transmembrane; HA, hemagglutinin; ELISA, enzyme-linked immunosorbent assay; WT, wild type; BIMU8, N- [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,3-dihydro-3-iso-propyl-2-oxo-1H-benzimidazol-1-carboxamide hydrochloride; (S)-zacopride, (S)-N-(1-azabicyclo-[2.2.2]oct-3-yl)-4-amino-5-chloro-2-methoxybenzamide monohydrochloride; cisapride, cis-4-amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)propyl]-3-methoxy-4-piperidinyl}-2-methoxy benzamide; RS 67333, 1-(4-amino-5-chloro-2-methoxy-phenyl)-3-(1-butyl-4-piperidinyl)-1-propanone; RO 116-1148 2,3-dihydrobenzo-(1,4)-dioxine-5-carboxylic acid 1-butylpiperidin-4-ylmethylamide hydrochloride; GR 113808, 1-methyl-1H-indole-3-carboxylic acid [1-2-[(methyl sulfonyl) amino] ethyl-4-piperidinyl] methyl ester; CSP-2503, 2-((4-(naphth-1-yl)piperazin-1-yl)methyl)-1,4-dioxoperhydropyrrolo(1,2-a)pyrazine.
- Received November 27, 2008.
- Accepted January 22, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|